Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 6, pp 1141–1149 | Cite as

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

  • Yun Leng
  • Jian Hou
  • Jie Jin
  • Mei Zhang
  • Xiaoyan Ke
  • Bin Jiang
  • Ling Pan
  • Linhua Yang
  • Fang Zhou
  • Jianmin Wang
  • Zhao Wang
  • Li Liu
  • Wei Li
  • Zhixiang Shen
  • Lugui Qiu
  • Naibai Chang
  • Jianyong Li
  • Jing Liu
  • Hongyan Pang
  • Haitao Meng
  • Peng Wei
  • Hua Jiang
  • Yan Liu
  • Xiangjun Zheng
  • Shifang Yang
  • Wenming Chen
Original Article

Abstract

Purpose

Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM). In this phase 2 study, the safety and efficacy of CPT in combination with thalidomide and dexamethasone (CPT + TD) was evaluated in patients with pretreated relapsed/refractory MM (RRMM).

Methods

Patients who received at least two previous therapies for MM were randomly assigned at a 2:1 ratio to receive treatment with CPT + TD or thalidomide and dexamethasone (TD). The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), duration of response (DOR) and safety.

Results

Overall, 47 patients were assigned to the CPT + TD group, and 24 patients were recruited to the TD group. The ORR in the CPT + TD group was 38.3 vs. 25.0% in the TD group. The median PFS time was 6.7 months for the CPT + TD group and 3.1 months for the TD group. The median DORs for the CPT + TD and TD groups were 7.1 and 3.2 months, respectively. Most of the adverse effects (AEs) were grade 1 or 2. Serious AEs were reported in 19.7% of the patients. No treatment-related deaths were reported.

Conclusion

CPT plus TD could serve as a new therapeutic strategy for patients with RRMM. A randomized, double-blind, placebo-controlled confirmatory study is currently under way.

Keywords

Recombinant human circularly permuted TRAIL Multiple myeloma Thalidomide Dexamethasone Phase 2 clinical trials 

Notes

Acknowledgements

The authors would like to thank all the patients and their families who contributed to the present study. The authors would like to thank all the staff members from the participating study sites.

Author contributions

Wenming Chen, Jian Hou, Shifang Yang and Xiangjun Zheng conceived, designed and performed the study; Yun Leng, Jian Hou, Jie Jin, Mei Zhang, Xiaoyan Ke, Bin Jiang, Ling Pan, Linhua Yang, Fang Zhou, Jianmin Wang, Zhao Wang, Li Liu, Wei Li, Zhixiang Shen, Lugui Qiu, Naibai Chang, Jianyong Li, Jing Liu, Haitao Meng, Hua Jiang, Yan Liu and Wenming Chen enrolled patients and collected data; Wenming Chen, Jian Hou, Shifang Yang, Xiangjun Zheng, Peng Wei and Hongyan Pang analyzed and interpreted the data; and all authors critically reviewed the manuscript for important intellectual content and approved the final draft.

Compliance with ethical standards

Conflict of interest

Beijing Sunbio Biotech Co. Ltd sponsored this clinical study and was responsible for medical monitoring and auditing. Shifang Yang, Xiangjun Zheng, Peng Wei and Hongyan Pang are employees of Beijing Sunbio Biotech Co., Ltd. All of the other authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365–382. doi: 10.1111/joim.12590 CrossRefPubMedGoogle Scholar
  2. 2.
    Kazandjian D, Landgren O (2016) A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol 43(6):682–689. doi: 10.1053/j.seminoncol.2016.10.008 CrossRefPubMedGoogle Scholar
  3. 3.
    Fang F, Wang AP, Yang SF (2005) Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Phamacologica Sinica 26:1373–1381. doi: 10.1111/j.1745-7254.2005.00206.x CrossRefGoogle Scholar
  4. 4.
    Zhou H, Li J, Jian Y et al (2016) Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Exp Hematol 44:125–131. doi: 10.1016/j.exphem.2015.10.004 CrossRefPubMedGoogle Scholar
  5. 5.
    Yan D, Ge Y, Deng H et al (2015) Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. Onco Targets Ther 8:1603–1610. doi: 10.2147/OTT.S73731 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38PubMedGoogle Scholar
  7. 7.
    Chen WM, Qiu LG, Hou J et al (2012) Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients. Blood 120:1857 (ASH annual meeting abstracts) Google Scholar
  8. 8.
    Leng Y, Qiu L, Hou J et al (2016) Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer 35:86. doi: 10.1186/s40880-016-0140-0 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Geng C, Hou J, Zhao Y et al (2014) A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol 89:1037–1042. doi: 10.1002/ajh.23822 CrossRefPubMedGoogle Scholar
  10. 10.
    Anderson KC, Alsina M, Bensinger W et al (2013) Multiple myeloma, version 1, 2013. J Natl Compr Canc Netw 11:11–17CrossRefPubMedGoogle Scholar
  11. 11.
    Chen W (2016) The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision): interpretation of the treatment of relapsing and refractory multiple myeloma. Zhonghua Nei Ke Za Zhi 55:93–94. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004 PubMedGoogle Scholar
  12. 12.
    Bladé J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102:1115–1123. doi: 10.1046/j.1365-2141.1998.00930.x CrossRefPubMedGoogle Scholar
  13. 13.
    Durie BG, Harousseau JL, Miguel JS, International Myeloma Working Group et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473. doi: 10.1038/sj.leu.2404284 CrossRefPubMedGoogle Scholar
  14. 14.
    Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399–403PubMedGoogle Scholar
  15. 15.
    Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991–995. doi: 10.1023/A:1011132808904 CrossRefPubMedGoogle Scholar
  16. 16.
    Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768–771. doi: 10.1046/j.1365-2141.2003.04345.x CrossRefPubMedGoogle Scholar
  17. 17.
    Chen WM, Wei P, Yang SF et al (2014) Transiently elevated AST/LDH are associated with clinical response to recombinant circularly permuted TRAIL (CPT) plus thalidomide in patients with relapsed and/or refractory multiple myeloma. Blood 124:3478 (ASH annual meeting abstracts) Google Scholar
  18. 18.
    Wei P, Yang S, Zheng X et al (2014) Transient elevation of AST or LDH as an early pharmacodynamic biomarker of recombinant circularly permuted trail (CPT) in treating patients with relapsed or refractory multiple myeloma. Haematologica 99:369 (19th congress of EHA Abstracts, Abstract P974) Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Yun Leng
    • 1
  • Jian Hou
    • 2
  • Jie Jin
    • 3
  • Mei Zhang
    • 4
  • Xiaoyan Ke
    • 5
  • Bin Jiang
    • 6
  • Ling Pan
    • 7
  • Linhua Yang
    • 8
  • Fang Zhou
    • 9
  • Jianmin Wang
    • 10
  • Zhao Wang
    • 11
  • Li Liu
    • 12
  • Wei Li
    • 13
  • Zhixiang Shen
    • 14
  • Lugui Qiu
    • 15
  • Naibai Chang
    • 16
  • Jianyong Li
    • 17
  • Jing Liu
    • 18
  • Hongyan Pang
    • 19
  • Haitao Meng
    • 3
  • Peng Wei
    • 19
  • Hua Jiang
    • 2
  • Yan Liu
    • 5
  • Xiangjun Zheng
    • 19
  • Shifang Yang
    • 19
  • Wenming Chen
    • 1
  1. 1.Department of Hematology, Beijing Chao-Yang HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of Hematology, Shanghai Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  3. 3.Department of Hematology, The First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina
  4. 4.Department of HematologyThe First Hospital of Xi’an Jiaotong UniversityXi’anChina
  5. 5.Department of Hematology and Lymphoma Research CenterPeking University Third HospitalBeijingChina
  6. 6.Department of HematologyPeking University People’s HospitalBeijingChina
  7. 7.Department of HemotologyWest China Hospital of Sichuan UniversityChengduChina
  8. 8.Department of HemotologyThe Second Hospital of Shanxi Medical UniversityTaiyuanChina
  9. 9.Department of HematologyJinan Military General HospitalJinanChina
  10. 10.Department of Hematology, Changhai HospitalSecond Military Medical UniversityShanghaiChina
  11. 11.Department of Hematology, Beijing Friendship HospitalCapital Medical UniversityBeijingChina
  12. 12.Department of Hematology, Tangdu HospitalFourth Military Medical UniversityXi’anChina
  13. 13.Department of HematologyThe First Hospital of Jilin UniversityChangchunChina
  14. 14.Department of Hematology, Ruijin HospitalShanghai Jiaotong UniversityShanghaiChina
  15. 15.Department of Lymphoma Center, Institute of Hematology and Blood Diseases HospitalCAMS & PUMCTianjinChina
  16. 16.Department of HematologyBeijing Hospital of the Ministry of HealthBeijingChina
  17. 17.Department of Hematology, Jiangsu Province HospitalThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  18. 18.Department of HematologyThe Third Xiangya Hospital of Central South UniversityChangshaChina
  19. 19.Beijing Sunbio Biotech Co. Ltd.BeijingChina

Personalised recommendations